All In Biotech

Drug Trial Radar · NCT04627428

Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

A Phase1/2a, Open-Label Study to Evaluate the Safety and Tolerability of RPE Stem Cell-derived RPE (RPESC-RPE) Transplantation as Therapy for Dry Age-related Macular Degeneration (AMD)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

18

Actual

Start

Apr 5, 2022

Primary completion

Aug 5, 2028

Study completion Aug 5, 2028

Sponsor

Lead sponsor
Luxa Biotechnology, LLCIndustry
Sponsor type
Industry
Collaborators
National Institutes of Health (NIH); National Eye Institute (NEI); Regenerative Research Foundation; California Institute for Regenerative Medicine (CIRM)
First posted
Nov 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.

Conditions

  • Dry Age-related Macular Degeneration

Interventions

  • RPESC-RPE-4WBiological

    RPESC-RPE-4W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of RPESC-RPE-4W transplantationTime frame: 24 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Retina Vitreous Associates Medical Group

    Beverly Hills, California

  • Spencer Center for Vision Research

    Palo Alto, California

  • University of Michigan Kellogg Eye Center

    Ann Arbor, Michigan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.